scholarly journals Causal relationship between the timing of menarche and young adult body mass index with consideration to a trend of consistently decreasing age at menarche

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0247757
Author(s):  
Hakyung Kim ◽  
Seung-Ah Choe ◽  
Soo Ji Lee ◽  
Joohon Sung

Younger age at menarche (AAM) is associated with higher body mass index (BMI) for young women. Considering that continuous trends in decreasing AAM and increasing BMI are found in many countries, we attempted to assess whether the observed negative association between AAM and young adult BMI is causal. We included 4,093 women from the Korean Genome and Epidemiology Study (KoGES) and Healthy twin Study (HTS) with relevant epidemiologic data and genome-wide marker information. To mitigate the remarkable differences in AAM across generations, we converted the AAM to a generation-standardized AAM (gsAAM). To test causality, we applied the Mendelian randomization (MR) approach, using a genetic risk score (GRS) based on 14 AAM-associated single nucleotide polymorphisms (SNPs). We constructed MR models adjusting for education level and validated the results using the inverse-variance weighted (IVW), weighted median (WM), MR-pleiotropy residual sum and outliers test (MR-PRESSO), and MR-Egger regression methods. We found a null association using observed AAM and BMI level (conventional regression; -0.05 [95% CIs -0.10–0.00] per 1-year higher AAM). This null association was replicated when gsAAM was applied instead of AAM. Using the two-stage least squares (2SLS) approach employing a univariate GRS, the association was also negated for both AAM and gsAAM, regardless of model specifications. All the MR diagnostics suggested statistically insignificant associations, but weakly negative trends, without evidence of confounding from pleiotropy. We did not observe a causal association between AAM and young adult BMI whether we considered the birth cohort effect or not. Our study alone does not exclude the possibility of existing a weak negative association, considering the modest power of our study design.

2017 ◽  
Vol 26 (6) ◽  
pp. 876-885 ◽  
Author(s):  
Brenda M. Birmann ◽  
Gabriella Andreotti ◽  
Anneclaire J. De Roos ◽  
Nicola J. Camp ◽  
Brian C.H. Chiu ◽  
...  

2014 ◽  
Vol 45 (1) ◽  
pp. 181-191 ◽  
Author(s):  
S. Walter ◽  
M. M. Glymour ◽  
K. Koenen ◽  
L. Liang ◽  
E. J. Tchetgen Tchetgen ◽  
...  

BackgroundObesity and anxiety are often linked but the direction of effects is not clear.MethodUsing genetic instrumental variable (IV) analyses in 5911 female participants from the Nurses' Health Study (NHS, initiated 1976) and 3697 male participants from the Health Professional Follow-up Study (HPFS, initiated 1986), we aimed to determine whether obesity increases symptoms of phobic anxiety. As instrumental variables we used the fat mass and obesity-associated (FTO) gene, the melanocortin 4 receptor (MC4R) gene and a genetic risk score (GRS) based on 32 single nucleotide polymorphisms (SNPs) that significantly predict body mass index (BMI). ‘Functional’ GRSs corresponding with specific biological pathways that shape BMI (adipogenesis, appetite and cardiopulmonary) were considered. The main outcome was phobic anxiety measured by the Crown Crisp Index (CCI) in 2004 in the NHS and in 2000 in the HPFS.ResultsIn observational analysis, a 1-unit higher BMI was associated with higher phobic anxiety symptoms [women:β = 0.05, 95% confidence interval (CI) 0.030–0.068; men:β = 0.04, 95% CI 0.016–0.071). IV analyses showed that BMI was associated with higher phobic anxiety symptoms in theFTO-instrumented analysis (p = 0.005) but not in the GRS-instrumented analysis (p = 0.256). Functional GRSs showed heterogeneous, non-significant effects of BMI on phobic anxiety symptoms.ConclusionsOur findings do not provide conclusive evidence in favor of the hypothesis that higher BMI leads to higher levels of phobic anxiety, but rather suggest that genes that influence obesity, in particularFTO, may have direct effects on phobic anxiety, and hence that obesity and phobic anxiety may share common genetic determinants.


Author(s):  
Alice Giontella ◽  
Luca A. Lotta ◽  
John D. Overton ◽  
Aris Baras ◽  
Pietro Minuz ◽  
...  

Background Different adiposity traits may be causally related to hypertension in different ways. By using genetic variants as randomly allocated proxies for studying the effect of modifying adiposity traits, the Mendelian randomization approach can be used to investigate this. Methods and Results In this study, we used 4 different genetic risk scores (GRS; GRS‐BMI 565 , GRS‐WHR 324 , GRS‐VAT 208 , GRS‐BF 81 ) including hundreds of single nucleotide polymorphisms associated with body mass index, waist‐to‐hip ratio, visceral adipose tissue, and body fat, respectively. These were applied as instrumental variables in Mendelian randomization analyses. Two Swedish urban‐based cohort studies, the Malmö Diet and Cancer, and the Malmö Preventive 795Projects were used to obtain genetic association estimates with blood pressure (BP). In both the Malmö Preventive Projects and Malmö Diet and Cancer studies, except for that for body fat, all of the genetic risk scores were significantly associated with systolic BP and diastolic BP, but with different magnitudes. In particular, in both cohorts, each standard deviation increase in the genetic risk score made up by the 324 single nucleotide polymorphisms associated with waist‐to‐hip ratio was associated with doubling of the likelihood of hypertension prevalence at baseline. However, only the genetic risk score made up by the 565 SNPs associated with body mass index was significantly associated with hypertension incidence during 23.6±4.3 years of follow‐up in the Malmö Preventive Project. Conclusions We support a causal link between genetically mediated adiposity, especially waist‐to‐hip ratio and body mass index, and BP traits including hypertension prevalence and, for the first time to our knowledge, hypertension incidence. The differences in magnitude between these associations might suggest different mechanisms by which different adiposity affects BP/hypertension and consequently may indicate that tailored interventions are needed to reduce cardiovascular risk.


2018 ◽  
Vol 13 (1) ◽  
Author(s):  
Richard J. Munthali ◽  
Venesa Sahibdeen ◽  
Juliana Kagura ◽  
Liesl M. Hendry ◽  
Shane A. Norris ◽  
...  

2018 ◽  
Vol 42 (9) ◽  
pp. 1574-1581 ◽  
Author(s):  
Dipender Gill ◽  
Christopher F. Brewer ◽  
Fabiola Del Greco M ◽  
Prasanthi Sivakumaran ◽  
Jack Bowden ◽  
...  

Sports ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 30
Author(s):  
Jenny M. Mahoney ◽  
Brett R. Baughman ◽  
Ailish C. Sheard ◽  
Brandon J. Sawyer

The aim of the present study was to assess the validity of verification phase (VP) testing and a 3 min all-out test to determine critical power (CP) in males with obesity. Nine young adult males with a body mass index (BMI) ≥ 30 kg·m−2 completed a cycle ergometer ramp-style VO2max test, four randomized VP tests at 80, 90, 100, and 105% of maximum wattage attained during the ramp test, and a 3 min all-out test. There was a significant main effect for VO2max across all five tests (p = 0.049). Individually, 8 of 9 participants attained a higher VO2max (L/min) during a VP test compared to the ramp test. A trend (p = 0.06) was observed for VO2max during the 90% VP test (3.61 ± 0.54 L/min) when compared to the ramp test (3.37 ± 0.39 L/min). A significantly higher VO2max (p = 0.016) was found in the VP tests that occurred below 130% of CP wattage (N = 15, VO2max = 3.76 ± 0.52 L/min) compared to those that were above (N = 21, VO2max = 3.36 ± 0.41 L/min). Our findings suggest submaximal VP tests at 90% may elicit the highest VO2max in males with obesity and there may be merit in using % of CP wattage to determine optimal VP intensity.


Sleep Health ◽  
2021 ◽  
Author(s):  
Bram J. Berntzen ◽  
E. Juulia Paavonen ◽  
Aila Rissanen ◽  
Jaakko Kaprio ◽  
Kirsi H. Pietiläinen

Sign in / Sign up

Export Citation Format

Share Document